Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 15166120)

1.

Administration of human insulin-like growth factor-binding protein-1 increases circulating levels of growth hormone in mice.

Cingel-Ristic V, Van Neck JW, Frystyk J, Drop SL, Flyvbjerg A.

Endocrinology. 2004 Sep;145(9):4401-7. Epub 2004 May 27.

PMID:
15166120
2.

Catch-Up Growth: Basic Mechanisms.

Griffin IJ.

Nestle Nutr Inst Workshop Ser. 2015;81:87-97. doi: 10.1159/000365806. Epub 2015 Jun 16.

PMID:
26111566
3.

The Effect of GHR/exon-3 Polymorphism and Serum GH, IGF-1 and IGFBP-3 Levels in Diabetes and Coronary Heart Disease.

Kucukhuseyin O, Toptas B, Timirci-Kahraman O, Isbir S, Karsidag K, Isbir T.

In Vivo. 2015 05-06;29(3):371-378.

PMID:
25977383
4.

Increased Linear Bone Growth by GH in the Absence of SOCS2 is Independent of IGF-1.

Dobie R, Ahmed SF, Staines KA, Pass C, Jasim S, MacRae VE, Farquharson C.

J Cell Physiol. 2015 Apr 1. doi: 10.1002/jcp.25006. [Epub ahead of print]

PMID:
25833299
5.

IGF-I regulates the age-dependent signaling peptide humanin.

Lee C, Wan J, Miyazaki B, Fang Y, Guevara-Aguirre J, Yen K, Longo V, Bartke A, Cohen P.

Aging Cell. 2014 Oct;13(5):958-61. doi: 10.1111/acel.12243. Epub 2014 Jul 18.

6.

The aging suppressor klotho: a potential regulator of growth hormone secretion.

Shahmoon S, Rubinfeld H, Wolf I, Cohen ZR, Hadani M, Shimon I, Rubinek T.

Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E326-34. doi: 10.1152/ajpendo.00090.2014. Epub 2014 Jun 17.

PMID:
24939736
7.

Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles.

List EO, Berryman DE, Funk K, Jara A, Kelder B, Wang F, Stout MB, Zhi X, Sun L, White TA, LeBrasseur NK, Pirtskhalava T, Tchkonia T, Jensen EA, Zhang W, Masternak MM, Kirkland JL, Miller RA, Bartke A, Kopchick JJ.

Endocrinology. 2014 May;155(5):1793-805. doi: 10.1210/en.2013-2086. Epub 2014 Feb 11.

8.
9.

An experimental model of partial insulin-like growth factor-1 deficiency in mice.

Castilla-Cortazar I, Guerra L, Puche JE, Muñoz U, Barhoum R, Escudero E, Lavandera JL.

J Physiol Biochem. 2014 Mar;70(1):129-39. doi: 10.1007/s13105-013-0287-y. Epub 2013 Sep 18.

PMID:
24043429
10.

Elevated GH/IGF-I, due to somatotrope-specific loss of both IGF-I and insulin receptors, alters glucose homeostasis and insulin sensitivity in a diet-dependent manner.

Gahete MD, Córdoba-Chacón J, Anadumaka CV, Lin Q, Brüning JC, Kahn CR, Luque RM, Kineman RD.

Endocrinology. 2011 Dec;152(12):4825-37. doi: 10.1210/en.2011-1447. Epub 2011 Oct 11.

11.

Liver-derived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH.

Nordstrom SM, Tran JL, Sos BC, Wagner KU, Weiss EJ.

Mol Endocrinol. 2011 Jul;25(7):1223-30. doi: 10.1210/me.2011-0047. Epub 2011 Apr 28.

12.

Human IGF binding protein-3 overexpression impairs glucose regulation in mice via an inhibition of insulin secretion.

Nguyen KH, Yao XH, Moulik S, Mishra S, Nyomba BL.

Endocrinology. 2011 Jun;152(6):2184-96. doi: 10.1210/en.2010-1324. Epub 2011 Mar 29.

PMID:
21447640
13.

Endocrine actions of myostatin: systemic regulation of the IGF and IGF binding protein axis.

Williams NG, Interlichia JP, Jackson MF, Hwang D, Cohen P, Rodgers BD.

Endocrinology. 2011 Jan;152(1):172-80. doi: 10.1210/en.2010-0488. Epub 2010 Dec 8.

14.

Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse model.

Romero CJ, Ng Y, Luque RM, Kineman RD, Koch L, Bruning JC, Radovick S.

Mol Endocrinol. 2010 May;24(5):1077-89. doi: 10.1210/me.2009-0393. Epub 2010 Mar 8.

15.

Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.

Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD.

Cancer Res. 2010 Feb 15;70(4):1564-72. doi: 10.1158/0008-5472.CAN-09-3228. Epub 2010 Feb 9.

16.

The role of liver-derived insulin-like growth factor-I.

Ohlsson C, Mohan S, Sjögren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J.

Endocr Rev. 2009 Aug;30(5):494-535. doi: 10.1210/er.2009-0010. Epub 2009 Jul 9. Review.

17.

Partial deletion of Pten in the hypothalamus leads to growth defects that cannot be rescued by exogenous growth hormone.

Choi D, Nguyen KT, Wang L, Schroer SA, Suzuki A, Mak TW, Woo M.

Endocrinology. 2008 Sep;149(9):4382-6. doi: 10.1210/en.2007-1761. Epub 2008 May 22.

PMID:
18499759
18.

Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.

Anzo M, Cobb LJ, Hwang DL, Mehta H, Said JW, Yakar S, LeRoith D, Cohen P.

Cancer Res. 2008 May 1;68(9):3342-9. doi: 10.1158/0008-5472.CAN-07-3165.

19.

Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression.

Liao L, Chen X, Wang S, Parlow AF, Xu J.

Mol Cell Biol. 2008 Apr;28(7):2460-9. doi: 10.1128/MCB.01163-07. Epub 2008 Jan 22.

20.

Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I.

Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO.

J Clin Endocrinol Metab. 2007 Nov;92(11):4172-9. Epub 2007 Aug 28.

PMID:
17726074
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk